AstraZeneca says Imfinzi plus Imdelltra improved survival in SCLC
AstraZeneca PLC said Imfinzi plus Imdelltra showed statistically significant and highly clinically meaningful improvements in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer.